Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: A report on behalf of eurocord and the acute leukemia working party of the european group for blood and marrow transplantation

Bone Marrow Transplantation

Volumn 49, Issue 7, 2014, Pages 887-894

  Tucunduva, L ^a,b   Ruggeri, A ^a,c   Sanz, G ^d   Furst, S ^e   Socie G ^a   Michallet, M ^f   Arcese, W ^c   Milpied, N ^g   Yakoub Agha, I ^h   Linkesch, W ⁱ   Cornelissen, J ^j   Mannone, L ^k   Iori, A P ^l   Ribera, J M ^m   Sanz, J ^d   Montesinos, P ^d   Purtill, D ^a   Labopin, M ⁿ   Gluckman, E ^a   Mohty, M ⁿ   Rocha, V ^a,b,o   more..

^a SAINT LOUIS HOSPITAL   (France)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e INSTITUT PAOLI CALMETTES   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ MEDICAL UNIVERSITY OF GRAZ   (Austria)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k Service d'Hématologie Clinique HÔpital Archet 1   (France)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁿ HÔPITAL SAINT ANTOINE   (France)

^o CHURCHILL HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; UNRELATED DONORS; ADOLESCENT; AGED; EUROPE; GRAFT VS HOST DISEASE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CORD BLOOD STEM CELL TRANSPLANTATION; EUROPE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UNRELATED DONORS; YOUNG ADULT;

EID: 84903842092     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.72     Document Type: Article

References (38)

1. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827-1833.
2. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075-4086.
3. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24: 460-466.
4. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009; 114: 5136-5145.
5. Nishiwaka S, Atsuta Y, Tanaka J. Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative ALL: what should we choose when no HLA matched related donor is available? Bone Marrow Transplant 2013; 48: 1369-1376.
6. Gupta V, Richards S, Rowe J. Acute Leukemia Stem Cell Transplantation Trialists' Collaborative G Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data metaanalysis. Blood 2013; 121: 339-350.
7. Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood 2013; 121: 1077-1082.
8. Gluckman E, Ruggeri A, Volt F, Cunha R, Boudjedir K, Rocha V. Milestones in umbilical cord blood transplantation. Br J Haematol 2011; 154: 441-447.
9. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. New Engl J Med 2004; 351: 2276-2285.
10. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653-660.
11. Atsuta Y, Morishima Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S et al. Comparison of unrelated cord blood transplantation and HLA-mismatched unrelated bone marrow transplantation for adults with leukemia. Biol Blood Marrow Transplant 2012; 18: 780-787.
12. Ferra C, Sanz J, Camara R, Sanz G, Bermudez A, Valcarcel D et al. Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source. Biol Blood Marrow Transplant 2010; 16: 957-966.
13. Ooi J, Takahashi S, Tomonari A, Tsukada N, Konuma T, Kato S et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with ALL. Bone Marrow Transplant 2009; 43: 455-459.
14. Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009; 113: 2902-2905.
15. Matsumura T, Kami M, Yamaguchi T, Yuji K, Kusumi E, Taniguchi S et al. Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: retrospective survey involving 256 patients in Japan. Leukemia 2012; 26: 1482-1486.
16. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
17. Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A populationbased cytogenetic study of adults with acute lymphoblastic leukemia. Blood 2010; 115: 206-214.
18. Oliansky DM, Larson RA, Weisdorf D, Dillon H, Ratko TA, Wall D et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transplant 2012; 18: 18-36 e6.
19. Marks DI, Wang T, Perez WS, Antin JH, Copelan E, Gale RP et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 2010; 116: 366-374.
20. Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004; 22: 2816-2825.
21. Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol 2009; 27: 3634-3641.
22. Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J et al. Reducedintensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010; 116: 4439-4443.
23. Nishiwaki S, Inamoto Y, Imamura M, Tsurumi H, Hatanaka K, Kawa K et al. Reduced-intensity versus conventional myeloablative conditioning for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in complete remission. Blood 2011; 117: 3698-3699.
24. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864.
25. Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti -T-cell globulin ATG-Fresenius. Blood 2011; 117: 6375-6382.
26. Siddiqi T, Blaise D. Hematopoietic stem cell transplantation II: toward safer allogeneic transplantation. Does antithymocyte globulin have a place in reducedintensity conditioning for allogeneic hematopoietic stem cell transplantation?. Hematology Am Soc Hematol Educ Program 2012; 2012: 246-250.
27. Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan KW et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004; 32: 397-407.
28. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611-1618.
29. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 256-263.
30. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versusleukemia effect in recipients of 2 units. Blood 2009; 114: 4293-4299.
31. Rocha V, Labopin M, Ruggeri A, Blaise D, Rio B, Cornelissen JJ et al. Outcomes After Double Cord Blood Transplantation Compared to Single Cord Blood Transplantation in Adults with Acute Leukemia Given a Reduced Intensity Conditioning Regimen. ASH Annu Meet Abstr 2012; 120: 232.
32. Scaradavou A, Brunstein CG, Eapen M, Le-Rademacher J, Barker JN, Chao N et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood 2013; 121: 752-758.
33. Wagner JE, Eapen M, Carter SL, Haut PR, Peres E, Schultz KR et al. No survival advantage after Double Umbilical Cord Blood (UCB) compared to single ucb transplant in children with hematological malignancy: results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) randomized trial. ASH Annu Meet Abstr 2012; 120: 359.
34. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood 2008; 111: 2563-2572.
35. Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández-Rivas JM, Moreno MJ et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005; 90: 1346-1356.
36. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24: 460-466.
37. Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010; 28: 3644-3652.
38. Bruggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 2012; 120: 4470-4481.